Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Dosage and route of administration: Infants \< 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m\^2 IV day 1 (max. dose 2 mg).

Dosage and route of administration: Infants \< 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants \> 1 year of age 75 mg/m\^2 CI over 48 hours, days 1-2.

Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.

Dosage and route of administration: Infants \< 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants \> 12 months of age 1800 mg/m\^2 IV over 60 minutes x 5 days, days 1-5.

Dosage and route of administration: Infants \< 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children \> 1 year 100 mg/m\^2 daily IV over 60 minutes days 1-5.

Dosage and route of administration: Temozolomide 100 mg/m\^2 PO once daily, days 1-5.

Dosage and route of administration: Temsirolimus 35 mg/m\^2 IV once day 1 and day 8.

Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.

Dosage and route of administration: 90 mg/m\^2/dose PO BID

If participant meets the criteria, they will have surgical resection of their tumor.

If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.